The European Society for Medical Oncology opened its annual meeting in Madrid, Spain, where nearly 40,000 attendees gathered to evaluate late-breaking clinical trial data. During the opening sessions of ESMO 2026, international research teams shared phase 3 findings that showed clear survival gains in multiple common solid tumors. Meeting chairs Fabrice André and James Larkin guided discussions on personalized mRNA vaccines, antibody-drug conjugates, and bispecific antibodies. The presentations outlined measurable drops in disease recurrence and death in several difficult cancer types [4].
ESMO 2026 Sessions Open in Madrid
The congress hall in Madrid drew large crowds as oncology specialists packed Presidential Symposium I to review late-breaking phase 3 clinical results. Co-chairs Fabrice André and James Larkin opened the morning gathering at the European Society for Medical Oncology congress. André and Larkin explained that each featured study evaluated a biological intervention against current standard care in solid tumors. The four selected trials examined distinct malignancies, including resected melanoma tumors, invasive urothelial bladder lesions, extensive small cell lung disease, and localized high-risk prostate cancer. Two of these trials, VOLGA and DeLLphi-305, yielded statistically significant overall survival gains at their planned interim looks [4].
The remaining pair of late-breaking presentations, INTerpath-001 and DASL-HiCaP, met their primary endpoints of recurrence-free survival and metastasis-free survival. While overall survival figures in those two groups had not crossed formal statistical boundaries at data cutoff, tumor control appeared durable during early observation. Reporting from Madrid for STAT, biopharma columnists Andrew Joseph and Adam Feuerstein, co-host of The Readout LOUD podcast who tracks Wall Street biotechnology, followed proceedings on site. Joseph and Feuerstein reported that ESMO 2026 drew nearly 40,000 participants to the Spanish capital [1].
Each late-breaking study focused on a distinct therapeutic mechanism instead of minor adjustments to older chemotherapy regimens. Clinical investigators evaluated an individualized mRNA neoantigen vaccine, an antibody-drug conjugate paired with immunotherapy, a bispecific T-cell engager, and an oral androgen receptor inhibitor. The findings showed that targeting tumor mutations or specific cell-surface proteins can improve outcomes for patients facing poor prognoses [4].
Melanoma Trial Benchmarks Personalized mRNA Vaccines
The phase 3 INTerpath-001 trial, sponsored by Moderna and Merck, evaluated whether adding an individualized mRNA neoantigen therapy could prevent disease recurrence after complete surgical resection. The double-blind study randomized 1137 patients with resected cutaneous melanoma in a 2:1 ratio to receive intismeran autogene or placebo, with both arms receiving pembrolizumab. Participants took 1 mg of intismeran by intramuscular injection every 3 weeks for 9 doses alongside intravenous pembrolizumab at 400 mg every 6 weeks for 9 cycles. All enrolled patients had an ECOG performance status of 0 or 1 and had received no prior systemic therapy before study entry [4].
Trial follow-up was 24.6 months. Across the study cohort assessed at the June 30, 2026 cutoff, intismeran paired with pembrolizumab decreased cancer return or death by 42%, demonstrating an adjusted hazard ratio of 0.58 with a 95% confidence interval between 0.45 and 0.75. After two years, recurrence-free survival stood at 82.2% in the neoantigen vaccine group against 70.0% in the placebo group. A piecewise examination revealed equivalent outcomes during the first six months with a hazard ratio of 0.99, followed by marked divergence favoring intismeran at a hazard ratio of 0.42. Distant metastasis-free survival favored the active combination at a hazard ratio of 0.62 [4].
Adverse events grade 3 to 5 occurred in 23.6% of patients given intismeran compared to 20.3% on placebo. Common side effects included pyrexia in 52.2% of patients and injection site pain in 51.0%. Adverse events led to death in 8 patients receiving intismeran compared to none on placebo. Study presenter Long said that INTerpath-001 “sets a new benchmark for adjuvant therapy in melanoma and established intismeran as a landmark advance in personalized cancer medicine” [4].
Bladder Cancer Cohort Tests Targeted Doublet
In muscle-invasive bladder cancer, cisplatin chemotherapy has long served as standard preoperative care, but many frail patients cannot tolerate its toxic renal effects. The phase 3 VOLGA trial tested whether perioperative immunotherapy paired with an antibody-drug conjugate could provide an effective alternative for this group. Investigators randomized 695 cisplatin-ineligible patients across three arms to receive either neoadjuvant durvalumab plus enfortumab vedotin followed by cystectomy and adjuvant durvalumab, the same combination with tremelimumab added, or radical cystectomy alone. At a March 2, 2026 data cutoff, the doublet cut the risk of event-free survival failure by 49% compared to surgery alone, recording a hazard ratio of 0.51 and p-value below 0.0001 [4].
Median event-free survival was not reached in the doublet arm compared to 12.1 months in the control group, with 24-month rates of 64% versus 45%. Overall survival also favored durvalumab and enfortumab vedotin, reaching 78% at 24 months compared to 69% for surgery alone, yielding a hazard ratio of 0.58 and a confidence interval between 0.40 and 0.83. Pathologic complete response rates reached 45% with the experimental doublet against 10% in the control cohort. Adding tremelimumab increased grade 3 or 4 adverse events to 70% without improving overall survival [4].
An exploratory blood analysis in 112 participants showed that 60% of patients with detectable circulating tumor DNA cleared the biomarker before surgery. Those patients achieved an 81% event-free survival rate at 24 months compared to 55% for participants with persistent circulating DNA. Study presenter Thomas Powles concluded that “VOLGA supports perioperative durvalumab plus 3 cycles of neoadjuvant enfortumab vedotin as a potential new standard of care for patients with muscle-invasive bladder cancer ineligible for or who refused cisplatin-based chemotherapy” [4].
Survival Outcomes in Lung and Prostate Trials
Small cell lung cancer has seen few treatment breakthroughs in recent decades, leaving patients with aggressive disease and limited maintenance options. In Presidential Symposium I, Jacob Sands of the Dana-Farber Cancer Institute presented primary analysis results from the phase 3 DeLLphi-305 trial, registered under study NCT06211036. The open-label study enrolled 563 patients with extensive-stage small cell lung cancer who had not progressed after first-line platinum, etoposide, and durvalumab. Participants received either the DLL3-directed bispecific T-cell engager tarlatamab, developed by Amgen as Imdelltra, combined with durvalumab or durvalumab monotherapy [4].
At a July 7, 2026 data cutoff with 16 months median follow-up, tarlatamab extended median overall survival to 21.1 months compared to 12.7 months with durvalumab alone, cutting the risk of death by 58% (HR, 0.42; 95% CI, 0.32-0.54; P < .001). Progression-free survival reached 7.4 months versus 1.9 months, with clear survival benefits observed in patients with baseline brain and liver metastases. Cytokine release syndrome occurred in 49.6% of patients on tarlatamab, with a single grade 3 event. Sands concluded that the results “support tarlatamab plus durvalumab as a new standard of care first-line maintenance therapy in extensive-stage small cell lung cancer” [4].
In localized prostate cancer, Tamim Niazi of McGill University and the Jewish General Hospital in Montreal presented interim findings from the phase 3 DASL-HiCaP trial, identified as study ANZUP1801 and NCT04136353. The study randomized 1106 men with very high-risk localized disease to receive radiation therapy and androgen deprivation therapy with darolutamide or placebo for 96 weeks. Therapy with darolutamide, known as Nubeqa, lowered metastatic spread or death by 58%, demonstrating an adjusted hazard ratio of 0.42 with confidence intervals spanning 0.27 to 0.66 at a p-value of 0.0001, lifting 4-year metastasis-free survival to 95% from 88% [4].
Tracking Molecular Residual Disease in ESMO 2026 Cohorts
Beyond drug therapies, advances in circulating tumor DNA testing drew close attention from oncologists seeking earlier warnings of cancer recurrence. Diagnostics company Natera presented data from 20 scientific abstracts at ESMO 2026 in Madrid, showcasing its Signatera Genome platform engineered with phased and structural variant sequencing. Analytical validation showed a limit of detection below 1 part per million, with sensitivity reaching below 1 part in 10 million. Natera chief medical officer Minetta Liu said that “the incorporation of phased and structural variants results in the ability to detect ctDNA significantly below 1 part per 10 million and takes MRD sensitivity into a range we haven’t seen before” [7].
Clinical cohorts presented in Madrid showed how high-sensitivity blood tests can anticipate clinical relapse months before radiological scans show new lesions. Scans often miss early recurrence. In the gastroesophageal cancer ICONIC study presented by Marco Gerlinger, the genomic assay detected all evaluable recurrences with a median lead time of more than 7.3 months over standard computed tomography scans. Similar monitoring was reported by Jonathan Spicer in the MDT-Bridge trial for non-small cell lung cancer, while Matthew D. Galsky analyzed molecular subtypes from the NIAGARA study in bladder cancer [7].
Can molecular testing also protect cancer survivors from unnecessary chemotherapy side effects? Findings from the phase 3 SAGITTARIUS trial presented by Vicente Alonso-Orduna demonstrated that genomic surveillance can guide safe treatment de-escalation in colon cancer. When oncologists reviewed post-operative molecular residual disease results, they altered their planned treatments for one in three patients. Among those treatment changes, 87% involved de-escalating therapy because the blood test showed no detectable tumor fragments. Researchers Hideaki Bando and Luca Lazzari similarly presented ctDNA data in colorectal cancer cohorts [7].
How Recent Congresses Compare
The progress reported in Madrid builds on therapeutic advances seen during previous European cancer meetings. Earlier meetings laid this groundwork. At the ESMO 2025 gathering in Berlin, researchers shared late-phase data for targeted inhibitors in advanced solid tumors. Sara A. Hurvitz of the Fred Hutchinson Cancer Center detailed the phase 3 VIKTORIA-1 study, registered as trial NCT05501886, where adding gedatolisib to fulvestrant and palbociclib yielded a median progression-free survival of 9.3 months versus 2.0 months with fulvestrant alone, producing a hazard ratio of 0.24. Thoracic oncologist Xiuning Le of MD Anderson Cancer Center in Houston reported an overall response rate of 64% with sevabertinib in pretreated HER2-mutant non-small cell lung cancer in the SOHO-01 trial [5].
At the same Berlin meeting, Dana-Farber investigator Erica Mayer of Harvard Medical School in Boston presented findings from the phase 3 evERA study, registered under study NCT05306340. Mayer reported that giredestrant plus everolimus improved progression-free survival to 8.77 months compared to 5.49 months with endocrine therapy in estrogen receptor-positive breast cancer. The oral combination reduced the risk of progression by 44% in the overall population and by 62% among patients with ESR1 mutations [5].
As STAT Plus biopharma columnists Andrew Joseph and Adam Feuerstein reported in coverage for The Readout LOUD, large pharmaceutical alliances now accelerate clinical validation of antibody-drug conjugates and bispecific constructs. Deals such as the $22 billion collaboration between Merck and Daiichi Sankyo show how developers are investing in modular oncology technologies [3]. Together with the phase 3 readouts from Madrid, these ongoing studies show that modern cancer medicine is progressing from broad cytotoxicity toward tailored immune activation and targeted molecular suppression [4].
- ONLINE NEWS Joseph, A., & Feuerstein, A. (2026, October 24). The ESMO presentation everyone’s been waiting for. STAT. [Article Link]
- ONLINE NEWS Joseph, A., & Feuerstein, A. (2026, October 24). The ESMO presentation everyone’s been waiting for. STAT. [Article Link]
- WEBSITE Joseph, A. (2026, January 1). ESMO Archives. STAT. [Article Link]
- ONLINE NEWS Serani, S. (2026, October 24). Late-breaking phase 3 data headline ESMO 2026 Presidential Symposium I. Targeted Oncology. [Article Link]
- ONLINE NEWS Hurvitz, S. A., Le, X., & Mayer, E. L. (2025, October 27). What were the key presentations at ESMO 2025? Oncology experts discuss. CancerNetwork. [Article Link]
- WEBSITE European Society for Medical Oncology. (2026, October 25). ESMO Virtual Plenaries. European Society for Medical Oncology. [Article Link]
- PRESS RELEASE Natera. (2026, October 21). ESMO 2026 presentations deepen the evidence base for Natera’s oncology portfolio and leadership in ultrasensitive MRD technology. Natera. [Article Link]
APA 7: PerEXP Teamworks. (2026, October 25). ESMO 2026 Congress Presents Phase 3 Oncology Data. PerEXP Teamworks. https://perexpteamworks.com/en/esmo-2026-cancer-trial-results/
